- Home
- AVIR
as 12-20-2024 3:31pm EST
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 247.5M | IPO Year: | 2020 |
| Target Price: | $6.88 | AVG Volume (30 days): | 491.5K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.75 - $4.60 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Atea Pharmaceuticals Inc. (AVIR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | AVIR | Director | Dec 10 '24 | Sell | $2.85 | 359,606 | $1,023,474.64 | 451,897 |
Latest Atea Pharmaceuticals Inc. News
AVIR Breaking Stock News: Dive into AVIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
TipRanks
17 days ago
Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir
Benzinga
18 days ago
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
GlobeNewswire
18 days ago
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
BioPharma Dive
18 days ago
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
GlobeNewswire
a month ago
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
Simply Wall St.
a month ago
Promising US Penny Stocks To Watch In November 2024
Zacks
a month ago
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Compare AVIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVIR Atea Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.